Global Radiopharmaceuticals in Nuclear Medicine Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029
Page: 121
Published Date: 03 Aug 2023
Category: Pharma & Healthcare
PDF Download
Get FREE Sample
Customize Request
-
Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Description
According to our (Global Info Research) latest study, the global Radiopharmaceuticals in Nuclear Medicine market size was valued at USD 4943.7 million in 2022 and is forecast to a readjusted size of USD 6857.2 million by 2029 with a CAGR of 4.8% during review period.
Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases. Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
The Global Info Research report includes an overview of the development of the Radiopharmaceuticals in Nuclear Medicine industry chain, the market status of Diagnostic Application (Diagnostic Radiopharmaceuticals, Therapy Radiopharmaceuticals), Therapeutic Application (Diagnostic Radiopharmaceuticals, Therapy Radiopharmaceuticals), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Radiopharmaceuticals in Nuclear Medicine.
Regionally, the report analyzes the Radiopharmaceuticals in Nuclear Medicine markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Radiopharmaceuticals in Nuclear Medicine market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Radiopharmaceuticals in Nuclear Medicine market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Radiopharmaceuticals in Nuclear Medicine industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K MT), revenue generated, and market share of different by Type (e.g., Diagnostic Radiopharmaceuticals, Therapy Radiopharmaceuticals).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Radiopharmaceuticals in Nuclear Medicine market.
Regional Analysis: The report involves examining the Radiopharmaceuticals in Nuclear Medicine market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Radiopharmaceuticals in Nuclear Medicine market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Radiopharmaceuticals in Nuclear Medicine:
Company Analysis: Report covers individual Radiopharmaceuticals in Nuclear Medicine manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Radiopharmaceuticals in Nuclear Medicine This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Diagnostic Application, Therapeutic Application).
Technology Analysis: Report covers specific technologies relevant to Radiopharmaceuticals in Nuclear Medicine. It assesses the current state, advancements, and potential future developments in Radiopharmaceuticals in Nuclear Medicine areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Radiopharmaceuticals in Nuclear Medicine market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Radiopharmaceuticals in Nuclear Medicine market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Diagnostic Radiopharmaceuticals
Therapy Radiopharmaceuticals
Enriched Stable Isotopes
Market segment by Application
Diagnostic Application
Therapeutic Application
Research
Pharmaceutical
Other
Major players covered
Bracco Imaging S.P.A.
Cambridge Isotope Laboratories, Inc.
Cardinal Health, Inc.
Covidien, Plc
Eczacibasi-Monrol
Fujifilm Holdings Corporation
GE Healthcare (Subsidiary Of General Electric Company)
IBA Group
Isotec, Inc. (Sigma-Aldrich)
Lantheus Medical Imaging, Inc.
Nordion, Inc.
Ntp Radioisotopes (Pty), Ltd.
Siemens Healthcare (Subsidiary Of Siemens AG)
Taiyo Nippon Sanso Corporation
Urenco Limited
Rotem Industries, Ltd., Inc.
Australian Nuclear Association And Technology Organization (ANSTO)
Board of Radiation And Isotope Technology (BRIT)
Institute of Atomic Energy Polatom Radioisotope Centre
Institute of Isotopes Co., Ltd.
Institute Of Radioelement (IRE)
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Radiopharmaceuticals in Nuclear Medicine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Radiopharmaceuticals in Nuclear Medicine, with price, sales, revenue and global market share of Radiopharmaceuticals in Nuclear Medicine from 2018 to 2023.
Chapter 3, the Radiopharmaceuticals in Nuclear Medicine competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Radiopharmaceuticals in Nuclear Medicine breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Radiopharmaceuticals in Nuclear Medicine market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Radiopharmaceuticals in Nuclear Medicine.
Chapter 14 and 15, to describe Radiopharmaceuticals in Nuclear Medicine sales channel, distributors, customers, research findings and conclusion.
Table of Contents
1 Market Overview
1.1 Product Overview and Scope of Radiopharmaceuticals in Nuclear Medicine
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Radiopharmaceuticals in Nuclear Medicine Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Diagnostic Radiopharmaceuticals
1.3.3 Therapy Radiopharmaceuticals
1.3.4 Enriched Stable Isotopes
1.4 Market Analysis by Application
1.4.1 Overview: Global Radiopharmaceuticals in Nuclear Medicine Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Diagnostic Application
1.4.3 Therapeutic Application
1.4.4 Research
1.4.5 Pharmaceutical
1.4.6 Other
1.5 Global Radiopharmaceuticals in Nuclear Medicine Market Size & Forecast
1.5.1 Global Radiopharmaceuticals in Nuclear Medicine Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Quantity (2018-2029)
1.5.3 Global Radiopharmaceuticals in Nuclear Medicine Average Price (2018-2029)
2.1 Bracco Imaging S.P.A.
2.1.1 Bracco Imaging S.P.A. Details
2.1.2 Bracco Imaging S.P.A. Major Business
2.1.3 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Product and Services
2.1.4 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Bracco Imaging S.P.A. Recent Developments/Updates
2.2 Cambridge Isotope Laboratories, Inc.
2.2.1 Cambridge Isotope Laboratories, Inc. Details
2.2.2 Cambridge Isotope Laboratories, Inc. Major Business
2.2.3 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Product and Services
2.2.4 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Cambridge Isotope Laboratories, Inc. Recent Developments/Updates
2.3 Cardinal Health, Inc.
2.3.1 Cardinal Health, Inc. Details
2.3.2 Cardinal Health, Inc. Major Business
2.3.3 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Product and Services
2.3.4 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Cardinal Health, Inc. Recent Developments/Updates
2.4 Covidien, Plc
2.4.1 Covidien, Plc Details
2.4.2 Covidien, Plc Major Business
2.4.3 Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Product and Services
2.4.4 Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Covidien, Plc Recent Developments/Updates
2.5 Eczacibasi-Monrol
2.5.1 Eczacibasi-Monrol Details
2.5.2 Eczacibasi-Monrol Major Business
2.5.3 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Product and Services
2.5.4 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Eczacibasi-Monrol Recent Developments/Updates
2.6 Fujifilm Holdings Corporation
2.6.1 Fujifilm Holdings Corporation Details
2.6.2 Fujifilm Holdings Corporation Major Business
2.6.3 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Product and Services
2.6.4 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Fujifilm Holdings Corporation Recent Developments/Updates
2.7 GE Healthcare (Subsidiary Of General Electric Company)
2.7.1 GE Healthcare (Subsidiary Of General Electric Company) Details
2.7.2 GE Healthcare (Subsidiary Of General Electric Company) Major Business
2.7.3 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Product and Services
2.7.4 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 GE Healthcare (Subsidiary Of General Electric Company) Recent Developments/Updates
2.8 IBA Group
2.8.1 IBA Group Details
2.8.2 IBA Group Major Business
2.8.3 IBA Group Radiopharmaceuticals in Nuclear Medicine Product and Services
2.8.4 IBA Group Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 IBA Group Recent Developments/Updates
2.9 Isotec, Inc. (Sigma-Aldrich)
2.9.1 Isotec, Inc. (Sigma-Aldrich) Details
2.9.2 Isotec, Inc. (Sigma-Aldrich) Major Business
2.9.3 Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Product and Services
2.9.4 Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Isotec, Inc. (Sigma-Aldrich) Recent Developments/Updates
2.10 Lantheus Medical Imaging, Inc.
2.10.1 Lantheus Medical Imaging, Inc. Details
2.10.2 Lantheus Medical Imaging, Inc. Major Business
2.10.3 Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Product and Services
2.10.4 Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Lantheus Medical Imaging, Inc. Recent Developments/Updates
2.11 Nordion, Inc.
2.11.1 Nordion, Inc. Details
2.11.2 Nordion, Inc. Major Business
2.11.3 Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Product and Services
2.11.4 Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Nordion, Inc. Recent Developments/Updates
2.12 Ntp Radioisotopes (Pty), Ltd.
2.12.1 Ntp Radioisotopes (Pty), Ltd. Details
2.12.2 Ntp Radioisotopes (Pty), Ltd. Major Business
2.12.3 Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Product and Services
2.12.4 Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Ntp Radioisotopes (Pty), Ltd. Recent Developments/Updates
2.13 Siemens Healthcare (Subsidiary Of Siemens AG)
2.13.1 Siemens Healthcare (Subsidiary Of Siemens AG) Details
2.13.2 Siemens Healthcare (Subsidiary Of Siemens AG) Major Business
2.13.3 Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Product and Services
2.13.4 Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Siemens Healthcare (Subsidiary Of Siemens AG) Recent Developments/Updates
2.14 Taiyo Nippon Sanso Corporation
2.14.1 Taiyo Nippon Sanso Corporation Details
2.14.2 Taiyo Nippon Sanso Corporation Major Business
2.14.3 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Product and Services
2.14.4 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Taiyo Nippon Sanso Corporation Recent Developments/Updates
2.15 Urenco Limited
2.15.1 Urenco Limited Details
2.15.2 Urenco Limited Major Business
2.15.3 Urenco Limited Radiopharmaceuticals in Nuclear Medicine Product and Services
2.15.4 Urenco Limited Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Urenco Limited Recent Developments/Updates
2.16 Rotem Industries, Ltd., Inc.
2.16.1 Rotem Industries, Ltd., Inc. Details
2.16.2 Rotem Industries, Ltd., Inc. Major Business
2.16.3 Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Product and Services
2.16.4 Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.16.5 Rotem Industries, Ltd., Inc. Recent Developments/Updates
2.17 Australian Nuclear Association And Technology Organization (ANSTO)
2.17.1 Australian Nuclear Association And Technology Organization (ANSTO) Details
2.17.2 Australian Nuclear Association And Technology Organization (ANSTO) Major Business
2.17.3 Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Product and Services
2.17.4 Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.17.5 Australian Nuclear Association And Technology Organization (ANSTO) Recent Developments/Updates
2.18 Board of Radiation And Isotope Technology (BRIT)
2.18.1 Board of Radiation And Isotope Technology (BRIT) Details
2.18.2 Board of Radiation And Isotope Technology (BRIT) Major Business
2.18.3 Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Product and Services
2.18.4 Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.18.5 Board of Radiation And Isotope Technology (BRIT) Recent Developments/Updates
2.19 Institute of Atomic Energy Polatom Radioisotope Centre
2.19.1 Institute of Atomic Energy Polatom Radioisotope Centre Details
2.19.2 Institute of Atomic Energy Polatom Radioisotope Centre Major Business
2.19.3 Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Product and Services
2.19.4 Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.19.5 Institute of Atomic Energy Polatom Radioisotope Centre Recent Developments/Updates
2.20 Institute of Isotopes Co., Ltd.
2.20.1 Institute of Isotopes Co., Ltd. Details
2.20.2 Institute of Isotopes Co., Ltd. Major Business
2.20.3 Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Product and Services
2.20.4 Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.20.5 Institute of Isotopes Co., Ltd. Recent Developments/Updates
2.21 Institute Of Radioelement (IRE)
2.21.1 Institute Of Radioelement (IRE) Details
2.21.2 Institute Of Radioelement (IRE) Major Business
2.21.3 Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Product and Services
2.21.4 Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.21.5 Institute Of Radioelement (IRE) Recent Developments/Updates
3.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Manufacturer (2018-2023)
3.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Manufacturer (2018-2023)
3.3 Global Radiopharmaceuticals in Nuclear Medicine Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Radiopharmaceuticals in Nuclear Medicine by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Radiopharmaceuticals in Nuclear Medicine Manufacturer Market Share in 2022
3.4.2 Top 6 Radiopharmaceuticals in Nuclear Medicine Manufacturer Market Share in 2022
3.5 Radiopharmaceuticals in Nuclear Medicine Market: Overall Company Footprint Analysis
3.5.1 Radiopharmaceuticals in Nuclear Medicine Market: Region Footprint
3.5.2 Radiopharmaceuticals in Nuclear Medicine Market: Company Product Type Footprint
3.5.3 Radiopharmaceuticals in Nuclear Medicine Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4.1 Global Radiopharmaceuticals in Nuclear Medicine Market Size by Region
4.1.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Region (2018-2029)
4.1.2 Global Radiopharmaceuticals in Nuclear Medicine Consumption Value by Region (2018-2029)
4.1.3 Global Radiopharmaceuticals in Nuclear Medicine Average Price by Region (2018-2029)
4.2 North America Radiopharmaceuticals in Nuclear Medicine Consumption Value (2018-2029)
4.3 Europe Radiopharmaceuticals in Nuclear Medicine Consumption Value (2018-2029)
4.4 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Consumption Value (2018-2029)
4.5 South America Radiopharmaceuticals in Nuclear Medicine Consumption Value (2018-2029)
4.6 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Consumption Value (2018-2029)
5.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Type (2018-2029)
5.2 Global Radiopharmaceuticals in Nuclear Medicine Consumption Value by Type (2018-2029)
5.3 Global Radiopharmaceuticals in Nuclear Medicine Average Price by Type (2018-2029)
6.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Application (2018-2029)
6.2 Global Radiopharmaceuticals in Nuclear Medicine Consumption Value by Application (2018-2029)
6.3 Global Radiopharmaceuticals in Nuclear Medicine Average Price by Application (2018-2029)
7.1 North America Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Type (2018-2029)
7.2 North America Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Application (2018-2029)
7.3 North America Radiopharmaceuticals in Nuclear Medicine Market Size by Country
7.3.1 North America Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Country (2018-2029)
7.3.2 North America Radiopharmaceuticals in Nuclear Medicine Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8.1 Europe Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Type (2018-2029)
8.2 Europe Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Application (2018-2029)
8.3 Europe Radiopharmaceuticals in Nuclear Medicine Market Size by Country
8.3.1 Europe Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Country (2018-2029)
8.3.2 Europe Radiopharmaceuticals in Nuclear Medicine Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9.1 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Market Size by Region
9.3.1 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10.1 South America Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Type (2018-2029)
10.2 South America Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Application (2018-2029)
10.3 South America Radiopharmaceuticals in Nuclear Medicine Market Size by Country
10.3.1 South America Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Country (2018-2029)
10.3.2 South America Radiopharmaceuticals in Nuclear Medicine Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11.1 Middle East & Africa Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Radiopharmaceuticals in Nuclear Medicine Market Size by Country
11.3.1 Middle East & Africa Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Radiopharmaceuticals in Nuclear Medicine Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12.1 Radiopharmaceuticals in Nuclear Medicine Market Drivers
12.2 Radiopharmaceuticals in Nuclear Medicine Market Restraints
12.3 Radiopharmaceuticals in Nuclear Medicine Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13.1 Raw Material of Radiopharmaceuticals in Nuclear Medicine and Key Manufacturers
13.2 Manufacturing Costs Percentage of Radiopharmaceuticals in Nuclear Medicine
13.3 Radiopharmaceuticals in Nuclear Medicine Production Process
13.4 Radiopharmaceuticals in Nuclear Medicine Industrial Chain
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Radiopharmaceuticals in Nuclear Medicine Typical Distributors
14.3 Radiopharmaceuticals in Nuclear Medicine Typical Customers
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Table of Figures
List of Tables
Table 1. Global Radiopharmaceuticals in Nuclear Medicine Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Radiopharmaceuticals in Nuclear Medicine Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Bracco Imaging S.P.A. Basic Information, Manufacturing Base and Competitors
Table 4. Bracco Imaging S.P.A. Major Business
Table 5. Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Product and Services
Table 6. Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Sales Quantity (K MT), Average Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Bracco Imaging S.P.A. Recent Developments/Updates
Table 8. Cambridge Isotope Laboratories, Inc. Basic Information, Manufacturing Base and Competitors
Table 9. Cambridge Isotope Laboratories, Inc. Major Business
Table 10. Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Product and Services
Table 11. Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Sales Quantity (K MT), Average Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Cambridge Isotope Laboratories, Inc. Recent Developments/Updates
Table 13. Cardinal Health, Inc. Basic Information, Manufacturing Base and Competitors
Table 14. Cardinal Health, Inc. Major Business
Table 15. Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Product and Services
Table 16. Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Sales Quantity (K MT), Average Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Cardinal Health, Inc. Recent Developments/Updates
Table 18. Covidien, Plc Basic Information, Manufacturing Base and Competitors
Table 19. Covidien, Plc Major Business
Table 20. Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Product and Services
Table 21. Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Sales Quantity (K MT), Average Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Covidien, Plc Recent Developments/Updates
Table 23. Eczacibasi-Monrol Basic Information, Manufacturing Base and Competitors
Table 24. Eczacibasi-Monrol Major Business
Table 25. Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Product and Services
Table 26. Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Sales Quantity (K MT), Average Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Eczacibasi-Monrol Recent Developments/Updates
Table 28. Fujifilm Holdings Corporation Basic Information, Manufacturing Base and Competitors
Table 29. Fujifilm Holdings Corporation Major Business
Table 30. Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Product and Services
Table 31. Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Sales Quantity (K MT), Average Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Fujifilm Holdings Corporation Recent Developments/Updates
Table 33. GE Healthcare (Subsidiary Of General Electric Company) Basic Information, Manufacturing Base and Competitors
Table 34. GE Healthcare (Subsidiary Of General Electric Company) Major Business
Table 35. GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Product and Services
Table 36. GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Sales Quantity (K MT), Average Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. GE Healthcare (Subsidiary Of General Electric Company) Recent Developments/Updates
Table 38. IBA Group Basic Information, Manufacturing Base and Competitors
Table 39. IBA Group Major Business
Table 40. IBA Group Radiopharmaceuticals in Nuclear Medicine Product and Services
Table 41. IBA Group Radiopharmaceuticals in Nuclear Medicine Sales Quantity (K MT), Average Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. IBA Group Recent Developments/Updates
Table 43. Isotec, Inc. (Sigma-Aldrich) Basic Information, Manufacturing Base and Competitors
Table 44. Isotec, Inc. (Sigma-Aldrich) Major Business
Table 45. Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Product and Services
Table 46. Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Sales Quantity (K MT), Average Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Isotec, Inc. (Sigma-Aldrich) Recent Developments/Updates
Table 48. Lantheus Medical Imaging, Inc. Basic Information, Manufacturing Base and Competitors
Table 49. Lantheus Medical Imaging, Inc. Major Business
Table 50. Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Product and Services
Table 51. Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Sales Quantity (K MT), Average Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Lantheus Medical Imaging, Inc. Recent Developments/Updates
Table 53. Nordion, Inc. Basic Information, Manufacturing Base and Competitors
Table 54. Nordion, Inc. Major Business
Table 55. Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Product and Services
Table 56. Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Sales Quantity (K MT), Average Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. Nordion, Inc. Recent Developments/Updates
Table 58. Ntp Radioisotopes (Pty), Ltd. Basic Information, Manufacturing Base and Competitors
Table 59. Ntp Radioisotopes (Pty), Ltd. Major Business
Table 60. Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Product and Services
Table 61. Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Sales Quantity (K MT), Average Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 62. Ntp Radioisotopes (Pty), Ltd. Recent Developments/Updates
Table 63. Siemens Healthcare (Subsidiary Of Siemens AG) Basic Information, Manufacturing Base and Competitors
Table 64. Siemens Healthcare (Subsidiary Of Siemens AG) Major Business
Table 65. Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Product and Services
Table 66. Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Sales Quantity (K MT), Average Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 67. Siemens Healthcare (Subsidiary Of Siemens AG) Recent Developments/Updates
Table 68. Taiyo Nippon Sanso Corporation Basic Information, Manufacturing Base and Competitors
Table 69. Taiyo Nippon Sanso Corporation Major Business
Table 70. Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Product and Services
Table 71. Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Sales Quantity (K MT), Average Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 72. Taiyo Nippon Sanso Corporation Recent Developments/Updates
Table 73. Urenco Limited Basic Information, Manufacturing Base and Competitors
Table 74. Urenco Limited Major Business
Table 75. Urenco Limited Radiopharmaceuticals in Nuclear Medicine Product and Services
Table 76. Urenco Limited Radiopharmaceuticals in Nuclear Medicine Sales Quantity (K MT), Average Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. Urenco Limited Recent Developments/Updates
Table 78. Rotem Industries, Ltd., Inc. Basic Information, Manufacturing Base and Competitors
Table 79. Rotem Industries, Ltd., Inc. Major Business
Table 80. Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Product and Services
Table 81. Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Sales Quantity (K MT), Average Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 82. Rotem Industries, Ltd., Inc. Recent Developments/Updates
Table 83. Australian Nuclear Association And Technology Organization (ANSTO) Basic Information, Manufacturing Base and Competitors
Table 84. Australian Nuclear Association And Technology Organization (ANSTO) Major Business
Table 85. Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Product and Services
Table 86. Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Sales Quantity (K MT), Average Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 87. Australian Nuclear Association And Technology Organization (ANSTO) Recent Developments/Updates
Table 88. Board of Radiation And Isotope Technology (BRIT) Basic Information, Manufacturing Base and Competitors
Table 89. Board of Radiation And Isotope Technology (BRIT) Major Business
Table 90. Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Product and Services
Table 91. Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Sales Quantity (K MT), Average Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 92. Board of Radiation And Isotope Technology (BRIT) Recent Developments/Updates
Table 93. Institute of Atomic Energy Polatom Radioisotope Centre Basic Information, Manufacturing Base and Competitors
Table 94. Institute of Atomic Energy Polatom Radioisotope Centre Major Business
Table 95. Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Product and Services
Table 96. Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Sales Quantity (K MT), Average Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 97. Institute of Atomic Energy Polatom Radioisotope Centre Recent Developments/Updates
Table 98. Institute of Isotopes Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 99. Institute of Isotopes Co., Ltd. Major Business
Table 100. Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Product and Services
Table 101. Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Sales Quantity (K MT), Average Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 102. Institute of Isotopes Co., Ltd. Recent Developments/Updates
Table 103. Institute Of Radioelement (IRE) Basic Information, Manufacturing Base and Competitors
Table 104. Institute Of Radioelement (IRE) Major Business
Table 105. Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Product and Services
Table 106. Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Sales Quantity (K MT), Average Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 107. Institute Of Radioelement (IRE) Recent Developments/Updates
Table 108. Global Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Manufacturer (2018-2023) & (K MT)
Table 109. Global Radiopharmaceuticals in Nuclear Medicine Revenue by Manufacturer (2018-2023) & (USD Million)
Table 110. Global Radiopharmaceuticals in Nuclear Medicine Average Price by Manufacturer (2018-2023) & (USD/MT)
Table 111. Market Position of Manufacturers in Radiopharmaceuticals in Nuclear Medicine, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 112. Head Office and Radiopharmaceuticals in Nuclear Medicine Production Site of Key Manufacturer
Table 113. Radiopharmaceuticals in Nuclear Medicine Market: Company Product Type Footprint
Table 114. Radiopharmaceuticals in Nuclear Medicine Market: Company Product Application Footprint
Table 115. Radiopharmaceuticals in Nuclear Medicine New Market Entrants and Barriers to Market Entry
Table 116. Radiopharmaceuticals in Nuclear Medicine Mergers, Acquisition, Agreements, and Collaborations
Table 117. Global Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Region (2018-2023) & (K MT)
Table 118. Global Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Region (2024-2029) & (K MT)
Table 119. Global Radiopharmaceuticals in Nuclear Medicine Consumption Value by Region (2018-2023) & (USD Million)
Table 120. Global Radiopharmaceuticals in Nuclear Medicine Consumption Value by Region (2024-2029) & (USD Million)
Table 121. Global Radiopharmaceuticals in Nuclear Medicine Average Price by Region (2018-2023) & (USD/MT)
Table 122. Global Radiopharmaceuticals in Nuclear Medicine Average Price by Region (2024-2029) & (USD/MT)
Table 123. Global Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Type (2018-2023) & (K MT)
Table 124. Global Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Type (2024-2029) & (K MT)
Table 125. Global Radiopharmaceuticals in Nuclear Medicine Consumption Value by Type (2018-2023) & (USD Million)
Table 126. Global Radiopharmaceuticals in Nuclear Medicine Consumption Value by Type (2024-2029) & (USD Million)
Table 127. Global Radiopharmaceuticals in Nuclear Medicine Average Price by Type (2018-2023) & (USD/MT)
Table 128. Global Radiopharmaceuticals in Nuclear Medicine Average Price by Type (2024-2029) & (USD/MT)
Table 129. Global Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Application (2018-2023) & (K MT)
Table 130. Global Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Application (2024-2029) & (K MT)
Table 131. Global Radiopharmaceuticals in Nuclear Medicine Consumption Value by Application (2018-2023) & (USD Million)
Table 132. Global Radiopharmaceuticals in Nuclear Medicine Consumption Value by Application (2024-2029) & (USD Million)
Table 133. Global Radiopharmaceuticals in Nuclear Medicine Average Price by Application (2018-2023) & (USD/MT)
Table 134. Global Radiopharmaceuticals in Nuclear Medicine Average Price by Application (2024-2029) & (USD/MT)
Table 135. North America Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Type (2018-2023) & (K MT)
Table 136. North America Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Type (2024-2029) & (K MT)
Table 137. North America Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Application (2018-2023) & (K MT)
Table 138. North America Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Application (2024-2029) & (K MT)
Table 139. North America Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Country (2018-2023) & (K MT)
Table 140. North America Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Country (2024-2029) & (K MT)
Table 141. North America Radiopharmaceuticals in Nuclear Medicine Consumption Value by Country (2018-2023) & (USD Million)
Table 142. North America Radiopharmaceuticals in Nuclear Medicine Consumption Value by Country (2024-2029) & (USD Million)
Table 143. Europe Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Type (2018-2023) & (K MT)
Table 144. Europe Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Type (2024-2029) & (K MT)
Table 145. Europe Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Application (2018-2023) & (K MT)
Table 146. Europe Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Application (2024-2029) & (K MT)
Table 147. Europe Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Country (2018-2023) & (K MT)
Table 148. Europe Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Country (2024-2029) & (K MT)
Table 149. Europe Radiopharmaceuticals in Nuclear Medicine Consumption Value by Country (2018-2023) & (USD Million)
Table 150. Europe Radiopharmaceuticals in Nuclear Medicine Consumption Value by Country (2024-2029) & (USD Million)
Table 151. Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Type (2018-2023) & (K MT)
Table 152. Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Type (2024-2029) & (K MT)
Table 153. Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Application (2018-2023) & (K MT)
Table 154. Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Application (2024-2029) & (K MT)
Table 155. Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Region (2018-2023) & (K MT)
Table 156. Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Region (2024-2029) & (K MT)
Table 157. Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Consumption Value by Region (2018-2023) & (USD Million)
Table 158. Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Consumption Value by Region (2024-2029) & (USD Million)
Table 159. South America Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Type (2018-2023) & (K MT)
Table 160. South America Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Type (2024-2029) & (K MT)
Table 161. South America Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Application (2018-2023) & (K MT)
Table 162. South America Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Application (2024-2029) & (K MT)
Table 163. South America Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Country (2018-2023) & (K MT)
Table 164. South America Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Country (2024-2029) & (K MT)
Table 165. South America Radiopharmaceuticals in Nuclear Medicine Consumption Value by Country (2018-2023) & (USD Million)
Table 166. South America Radiopharmaceuticals in Nuclear Medicine Consumption Value by Country (2024-2029) & (USD Million)
Table 167. Middle East & Africa Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Type (2018-2023) & (K MT)
Table 168. Middle East & Africa Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Type (2024-2029) & (K MT)
Table 169. Middle East & Africa Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Application (2018-2023) & (K MT)
Table 170. Middle East & Africa Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Application (2024-2029) & (K MT)
Table 171. Middle East & Africa Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Region (2018-2023) & (K MT)
Table 172. Middle East & Africa Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Region (2024-2029) & (K MT)
Table 173. Middle East & Africa Radiopharmaceuticals in Nuclear Medicine Consumption Value by Region (2018-2023) & (USD Million)
Table 174. Middle East & Africa Radiopharmaceuticals in Nuclear Medicine Consumption Value by Region (2024-2029) & (USD Million)
Table 175. Radiopharmaceuticals in Nuclear Medicine Raw Material
Table 176. Key Manufacturers of Radiopharmaceuticals in Nuclear Medicine Raw Materials
Table 177. Radiopharmaceuticals in Nuclear Medicine Typical Distributors
Table 178. Radiopharmaceuticals in Nuclear Medicine Typical Customers
List of Figures
Figure 1. Radiopharmaceuticals in Nuclear Medicine Picture
Figure 2. Global Radiopharmaceuticals in Nuclear Medicine Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Radiopharmaceuticals in Nuclear Medicine Consumption Value Market Share by Type in 2022
Figure 4. Diagnostic Radiopharmaceuticals Examples
Figure 5. Therapy Radiopharmaceuticals Examples
Figure 6. Enriched Stable Isotopes Examples
Figure 7. Global Radiopharmaceuticals in Nuclear Medicine Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 8. Global Radiopharmaceuticals in Nuclear Medicine Consumption Value Market Share by Application in 2022
Figure 9. Diagnostic Application Examples
Figure 10. Therapeutic Application Examples
Figure 11. Research Examples
Figure 12. Pharmaceutical Examples
Figure 13. Other Examples
Figure 14. Global Radiopharmaceuticals in Nuclear Medicine Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 15. Global Radiopharmaceuticals in Nuclear Medicine Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 16. Global Radiopharmaceuticals in Nuclear Medicine Sales Quantity (2018-2029) & (K MT)
Figure 17. Global Radiopharmaceuticals in Nuclear Medicine Average Price (2018-2029) & (USD/MT)
Figure 18. Global Radiopharmaceuticals in Nuclear Medicine Sales Quantity Market Share by Manufacturer in 2022
Figure 19. Global Radiopharmaceuticals in Nuclear Medicine Consumption Value Market Share by Manufacturer in 2022
Figure 20. Producer Shipments of Radiopharmaceuticals in Nuclear Medicine by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 21. Top 3 Radiopharmaceuticals in Nuclear Medicine Manufacturer (Consumption Value) Market Share in 2022
Figure 22. Top 6 Radiopharmaceuticals in Nuclear Medicine Manufacturer (Consumption Value) Market Share in 2022
Figure 23. Global Radiopharmaceuticals in Nuclear Medicine Sales Quantity Market Share by Region (2018-2029)
Figure 24. Global Radiopharmaceuticals in Nuclear Medicine Consumption Value Market Share by Region (2018-2029)
Figure 25. North America Radiopharmaceuticals in Nuclear Medicine Consumption Value (2018-2029) & (USD Million)
Figure 26. Europe Radiopharmaceuticals in Nuclear Medicine Consumption Value (2018-2029) & (USD Million)
Figure 27. Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Consumption Value (2018-2029) & (USD Million)
Figure 28. South America Radiopharmaceuticals in Nuclear Medicine Consumption Value (2018-2029) & (USD Million)
Figure 29. Middle East & Africa Radiopharmaceuticals in Nuclear Medicine Consumption Value (2018-2029) & (USD Million)
Figure 30. Global Radiopharmaceuticals in Nuclear Medicine Sales Quantity Market Share by Type (2018-2029)
Figure 31. Global Radiopharmaceuticals in Nuclear Medicine Consumption Value Market Share by Type (2018-2029)
Figure 32. Global Radiopharmaceuticals in Nuclear Medicine Average Price by Type (2018-2029) & (USD/MT)
Figure 33. Global Radiopharmaceuticals in Nuclear Medicine Sales Quantity Market Share by Application (2018-2029)
Figure 34. Global Radiopharmaceuticals in Nuclear Medicine Consumption Value Market Share by Application (2018-2029)
Figure 35. Global Radiopharmaceuticals in Nuclear Medicine Average Price by Application (2018-2029) & (USD/MT)
Figure 36. North America Radiopharmaceuticals in Nuclear Medicine Sales Quantity Market Share by Type (2018-2029)
Figure 37. North America Radiopharmaceuticals in Nuclear Medicine Sales Quantity Market Share by Application (2018-2029)
Figure 38. North America Radiopharmaceuticals in Nuclear Medicine Sales Quantity Market Share by Country (2018-2029)
Figure 39. North America Radiopharmaceuticals in Nuclear Medicine Consumption Value Market Share by Country (2018-2029)
Figure 40. United States Radiopharmaceuticals in Nuclear Medicine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Canada Radiopharmaceuticals in Nuclear Medicine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 42. Mexico Radiopharmaceuticals in Nuclear Medicine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 43. Europe Radiopharmaceuticals in Nuclear Medicine Sales Quantity Market Share by Type (2018-2029)
Figure 44. Europe Radiopharmaceuticals in Nuclear Medicine Sales Quantity Market Share by Application (2018-2029)
Figure 45. Europe Radiopharmaceuticals in Nuclear Medicine Sales Quantity Market Share by Country (2018-2029)
Figure 46. Europe Radiopharmaceuticals in Nuclear Medicine Consumption Value Market Share by Country (2018-2029)
Figure 47. Germany Radiopharmaceuticals in Nuclear Medicine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. France Radiopharmaceuticals in Nuclear Medicine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. United Kingdom Radiopharmaceuticals in Nuclear Medicine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Russia Radiopharmaceuticals in Nuclear Medicine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 51. Italy Radiopharmaceuticals in Nuclear Medicine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 52. Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Sales Quantity Market Share by Type (2018-2029)
Figure 53. Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Sales Quantity Market Share by Application (2018-2029)
Figure 54. Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Sales Quantity Market Share by Region (2018-2029)
Figure 55. Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Consumption Value Market Share by Region (2018-2029)
Figure 56. China Radiopharmaceuticals in Nuclear Medicine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Japan Radiopharmaceuticals in Nuclear Medicine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Korea Radiopharmaceuticals in Nuclear Medicine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. India Radiopharmaceuticals in Nuclear Medicine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. Southeast Asia Radiopharmaceuticals in Nuclear Medicine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 61. Australia Radiopharmaceuticals in Nuclear Medicine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 62. South America Radiopharmaceuticals in Nuclear Medicine Sales Quantity Market Share by Type (2018-2029)
Figure 63. South America Radiopharmaceuticals in Nuclear Medicine Sales Quantity Market Share by Application (2018-2029)
Figure 64. South America Radiopharmaceuticals in Nuclear Medicine Sales Quantity Market Share by Country (2018-2029)
Figure 65. South America Radiopharmaceuticals in Nuclear Medicine Consumption Value Market Share by Country (2018-2029)
Figure 66. Brazil Radiopharmaceuticals in Nuclear Medicine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 67. Argentina Radiopharmaceuticals in Nuclear Medicine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 68. Middle East & Africa Radiopharmaceuticals in Nuclear Medicine Sales Quantity Market Share by Type (2018-2029)
Figure 69. Middle East & Africa Radiopharmaceuticals in Nuclear Medicine Sales Quantity Market Share by Application (2018-2029)
Figure 70. Middle East & Africa Radiopharmaceuticals in Nuclear Medicine Sales Quantity Market Share by Region (2018-2029)
Figure 71. Middle East & Africa Radiopharmaceuticals in Nuclear Medicine Consumption Value Market Share by Region (2018-2029)
Figure 72. Turkey Radiopharmaceuticals in Nuclear Medicine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. Egypt Radiopharmaceuticals in Nuclear Medicine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. Saudi Arabia Radiopharmaceuticals in Nuclear Medicine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 75. South Africa Radiopharmaceuticals in Nuclear Medicine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 76. Radiopharmaceuticals in Nuclear Medicine Market Drivers
Figure 77. Radiopharmaceuticals in Nuclear Medicine Market Restraints
Figure 78. Radiopharmaceuticals in Nuclear Medicine Market Trends
Figure 79. Porters Five Forces Analysis
Figure 80. Manufacturing Cost Structure Analysis of Radiopharmaceuticals in Nuclear Medicine in 2022
Figure 81. Manufacturing Process Analysis of Radiopharmaceuticals in Nuclear Medicine
Figure 82. Radiopharmaceuticals in Nuclear Medicine Industrial Chain
Figure 83. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 84. Direct Channel Pros & Cons
Figure 85. Indirect Channel Pros & Cons
Figure 86. Methodology
Figure 87. Research Process and Data Source
Research Methodology
Client Requirements
Review and analyze client requirements
Discussion of all the project requirements and queries
Flexibility Check
Project Feasibility Analysis
Finalizing tentative research programme
Structuring project proposal with scope, timeline, and costs
Analyzing Market Dynamics
Determination of key drivers, restraints, challenge, and opportunity
Identifies market needs and trends
Market Size Estimation & Forecast
Estimation of historical data based on secondary and primary data
Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)
Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies
Consideration of geography, region-specific product/service demand for region segments
Consideration of product utilization rates, product demand outlook for segments by application or end-user.
Data Source
Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports,
paid database, press releases, blogs, newsletters,and GIR repositories.
Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts
to verify insights.
Validation
and
triangulation of
secondary and primary source.
Collection of data
Cumulating and collating the essential qualitative and quantitative data
Generation of report in client requested format by research analysts
Reviews by expert analysts
Final quality check
Clarifying queries
Receiving feedback
Ensuring satisfaction
01 Identification of data
This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
-
02 Evaluation of Market Dynamic
This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
-
03 Collection of Data
This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
-
04 Collaboration of Data
This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis
This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.
Companies Mentioned
Bracco Imaging S.P.A. Cambridge Isotope Laboratories, Inc. Cardinal Health, Inc. Covidien, Plc Eczacibasi-Monrol Fujifilm Holdings Corporation GE Healthcare (Subsidiary Of General Electric Company) IBA Group Isotec, Inc. (Sigma-Aldrich) Lantheus Medical Imaging, Inc. Nordion, Inc. Ntp Radioisotopes (Pty), Ltd. Siemens Healthcare (Subsidiary Of Siemens AG) Taiyo Nippon Sanso Corporation Urenco Limited Rotem Industries, Ltd., Inc. Australian Nuclear Association And Technology Organization (ANSTO) Board of Radiation And Isotope Technology (BRIT) Institute of Atomic Energy Polatom Radioisotope Centre Institute of Isotopes Co., Ltd. Institute Of Radioelement (IRE)
Related Reports
03 Aug 2023
Pharma & Healthcare
Purchase Options
Add To Cart
Buy Now
Popular Product Keywords
- We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.Speak to our analyst >>
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
Insight into the industry market information
Analyze market development needs
Prospects for future development
Develop industry investment strategy
- Digging deeper into global industry information and providing market strategies.Contact Us >>
